Chronic myeloid leukemia in Nigerian patients: Anemia is an independent predictor of overall survival

Clinical Medicine Insights: Blood Disorders

Volumn 9, Issue , 2016, Pages 9-13

  Oyekunle, Anthony A ^a,b   Durosinmi, Muheez A ^a,b   Bolarinwa, Ramoni A ^a,b   Owojuyigbe, Temilola ^a,b   Salawu, Lateef ^a,b   Akinola, Norah O ^a,b  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITALS COMPLEX   (Nigeria)

Author keywords

Anemia; Chronic myeloid leukemia; Imatinib; Nigeria; Survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGERIAN; OVERALL SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME;

EID: 84976451961     PISSN: None     EISSN: 1179545X     Source Type: Journal    
DOI: 10.4137/CMBD.S31562     Document Type: Article

References (20)

1. Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
2. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-1042.
3. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. ASH Hematol. 2003;2003:132-152.
4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-652.
5. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology. 1999;13:169-184.
6. Boma PO, Durosinmi MA, Adediran IA, Akinola NO, Salawu L. Clinical and prognostic features of Nigerians with chronic myeloid leukemia. Niger Postgrad Med J. 2006;13(1):47-52.
7. Okanny CC, Durosinmi MA, Chukwuani CM, et al. Interferon alfa-2a (Roferon-A) monotherapy in chronic myelogenous leukemia: a pilot study in Nigerian patients in early chronic phase. West Afr J Med. 2000;19(4):286-292.
8. Oyekunle AA, Zander AR, Binder M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2012;92(4):487-496.
9. Oyekunle A, Klyuchnikov E, Ocheni S, et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol. 2011;126(1):30-39.
10. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1008.
11. Druker BJ, Guilhot F, O’Brien SG, et al. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. J Clin Oncol. 2006; 24(18 suppl):6506.
12. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
13. Gambacorti-Passerini C, Antolini L, Mahon F-X, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:1-9.
14. Durosinmi M, Faluyi J, Oyekunle A, Salawu L, Adediran I, Akinola N. The use of Imatinib mesylate (Glivec) in Nigerian patients with chronic myeloid leukemia. Cellular Therapy Transpl. 2008;1(2):10.3205.
15. Oyekunle AA, Bolarinwa RAA, Oyelese AT, Salawu L, Durosinmi MA. Determinants of overall and progression-free survival of Nigerian patients with Philadelphia-positive chronic myeloid leukemia. Adv Hematol. 2015;2015:5.
16. Wikipedia Contributors. Demographics of Nigeria. In: 18 May 2014 00:36 UTC ed: Wikipedia, The Free Encyclopedia; 2014.
17. Koffi KG, Nanlo DC, N’dathz E, et al. The effect of Imatinib Mesylate for newly diagnosed philadelphia chromosome-positive, chronic-phase myeloid leukemia in Sub-Saharan African patients: the experience of cote d’Ivoire. Adv Hematol. 2010;2010:6.
18. Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013;37(3):247-254.
19. Oyekunle AA, Osho PO, Aneke JC, Salawu L, Durosinmi MA. The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era. J Hematol Malignancies. 2012;2(2):25.
20. Saußele S, Krauß M-P, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126(1):42-49.